JP7152393B2 - 医薬化合物 - Google Patents

医薬化合物 Download PDF

Info

Publication number
JP7152393B2
JP7152393B2 JP2019520588A JP2019520588A JP7152393B2 JP 7152393 B2 JP7152393 B2 JP 7152393B2 JP 2019520588 A JP2019520588 A JP 2019520588A JP 2019520588 A JP2019520588 A JP 2019520588A JP 7152393 B2 JP7152393 B2 JP 7152393B2
Authority
JP
Japan
Prior art keywords
dimethylisoxazol
benzo
pyrrolidin
imidazol
methylsulfonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019520588A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019537571A5 (enExample
JP2019537571A (ja
Inventor
アンソニー ペッグ、ネイル
トーマス オニオンズ、スチュアート
マイケル エイドリアン タッディ、デイヴィッド
シャノン、ジョナサン
パオレッタ、シルヴィア
ジェームス ブラウン、リチャード
スミス、ドン
ハーボトル、ガレス
Original Assignee
セルセントリック・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セルセントリック・リミテッド filed Critical セルセントリック・リミテッド
Publication of JP2019537571A publication Critical patent/JP2019537571A/ja
Publication of JP2019537571A5 publication Critical patent/JP2019537571A5/ja
Application granted granted Critical
Publication of JP7152393B2 publication Critical patent/JP7152393B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019520588A 2016-10-18 2017-10-18 医薬化合物 Active JP7152393B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1617630.7A GB201617630D0 (en) 2016-10-18 2016-10-18 Pharmaceutical compounds
GB1617630.7 2016-10-18
PCT/GB2017/053152 WO2018073586A1 (en) 2016-10-18 2017-10-18 Pharmaceutical compounds

Publications (3)

Publication Number Publication Date
JP2019537571A JP2019537571A (ja) 2019-12-26
JP2019537571A5 JP2019537571A5 (enExample) 2020-11-26
JP7152393B2 true JP7152393B2 (ja) 2022-10-12

Family

ID=57680668

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019520588A Active JP7152393B2 (ja) 2016-10-18 2017-10-18 医薬化合物

Country Status (24)

Country Link
US (2) US10696666B2 (enExample)
EP (1) EP3529248B1 (enExample)
JP (1) JP7152393B2 (enExample)
KR (1) KR102578786B1 (enExample)
CN (1) CN110049983B (enExample)
AU (1) AU2017346453B2 (enExample)
CA (1) CA3039641A1 (enExample)
CY (1) CY1123666T1 (enExample)
DK (1) DK3529248T3 (enExample)
EA (1) EA201990643A1 (enExample)
ES (1) ES2828504T3 (enExample)
GB (1) GB201617630D0 (enExample)
HR (1) HRP20201444T1 (enExample)
HU (1) HUE052443T2 (enExample)
IL (1) IL266017B (enExample)
LT (1) LT3529248T (enExample)
MX (1) MX384438B (enExample)
PT (1) PT3529248T (enExample)
RS (1) RS61007B1 (enExample)
SG (1) SG11201903155XA (enExample)
SI (1) SI3529248T1 (enExample)
SM (1) SMT202000593T1 (enExample)
WO (1) WO2018073586A1 (enExample)
ZA (1) ZA201902334B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201617630D0 (en) 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
GB201617627D0 (en) * 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
TWI795440B (zh) 2017-09-15 2023-03-11 美商佛瑪治療公司 作為ＣＢＰ／ｐ３００抑制劑之四氫─咪唑並喹啉化合物
GB201806320D0 (en) * 2018-04-18 2018-05-30 Cellcentric Ltd Process
CN116178369A (zh) 2018-06-29 2023-05-30 福马疗法公司 抑制creb结合蛋白(cbp)
AR118362A1 (es) 2019-03-15 2021-09-29 Forma Therapeutics Inc Inhibición de la proteína de unión al elemento de respuesta a amp cíclico (creb)
MX2021010829A (es) * 2019-03-15 2021-12-10 Forma Therapeutics Inc Inhibición de la proteína de unión al elemento de respuesta a adenosín monofosfato (amp) cíclica (creb).
CN112574189B (zh) * 2019-09-27 2024-05-31 海创药业股份有限公司 一种ep300/cbp抑制剂
CN112574191B (zh) * 2019-09-29 2024-01-23 南京圣和药业股份有限公司 异噁唑杂环类化合物及其应用
AU2021298153A1 (en) 2020-06-25 2023-02-23 Tolremo Therapeutics Ag A combination of a CBP/p300 bromodomain inhibitor and an EGFR inhibitor for use in treating EGFR-mutant NSCLC
IL299344A (en) 2020-06-25 2023-02-01 Tolremo Therapeutics Ag Combination of a cbp/p300 bromodomain inhibitor and a kras inhibitor for the treatment of cancer
US11795168B2 (en) 2020-09-23 2023-10-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
US11801243B2 (en) 2020-09-23 2023-10-31 Forma Therapeutics, Inc. Bromodomain inhibitors for androgen receptor-driven cancers
TW202227429A (zh) * 2020-11-06 2022-07-16 大陸商貝達藥業股份有限公司 Ｐ３００抑制劑、包含其的藥物組合物、其應用及製備其的方法
US20240122941A1 (en) * 2020-12-25 2024-04-18 National Cancer Center Therapy based on synthetic lethality in swi/snf complex-dysfunction cancer
CN116670129A (zh) * 2020-12-31 2023-08-29 南京明德新药研发有限公司 苯并咪唑类化合物及其应用
CN114989158A (zh) * 2021-03-02 2022-09-02 复旦大学 组蛋白乙酰转移酶p300溴结构域抑制剂及其药用组合物及其应用
WO2022184664A1 (en) 2021-03-02 2022-09-09 Boehringer Ingelheim International Gmbh Anticancer combination therapy
EP4257130A1 (de) * 2022-04-08 2023-10-11 Justus-Liebig-Universität Gießen Inobrodib zur behandlung von pulmonaler arterieller hypertonie

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016086200A1 (en) 2014-11-27 2016-06-02 Genentech, Inc. 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
WO2016170323A1 (en) 2015-04-20 2016-10-27 Cellcentric Ltd Isoxazolyl substituted imidazopyridines
WO2016170324A1 (en) 2015-04-20 2016-10-27 Cellcentric Ltd Isoxazolyl substituted benzimidazoles
WO2018073587A1 (en) 2016-10-18 2018-04-26 Cellcentric Ltd Pharmaceutical compounds

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL113472A0 (en) 1994-04-29 1995-07-31 Lilly Co Eli Non-peptidyl tachykinin receptor antogonists
EP1206265B1 (en) * 1999-06-30 2003-11-12 Merck & Co., Inc. Src kinase inhibitor compounds
KR20030060904A (ko) 2000-10-06 2003-07-16 뉴로젠 코포레이션 Ｃｒｆ 수용체 조절자로서 벤즈이미다졸 및 인돌 유도체
WO2002072549A1 (en) 2001-03-12 2002-09-19 Millennium Pharmaceuticals, Inc. Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
JP2005523292A (ja) 2002-02-21 2005-08-04 イーライ・リリー・アンド・カンパニー ペルオキシソーム増殖因子活性化受容体モジュレーター
WO2004063151A2 (en) 2003-01-03 2004-07-29 Bristol-Myers Squibb Company Novel tyrosine kinase inhibitors
US7312215B2 (en) 2003-07-29 2007-12-25 Bristol-Myers Squibb Company Benzimidazole C-2 heterocycles as kinase inhibitors
WO2005118555A1 (en) 2004-06-04 2005-12-15 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2006124780A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Ih-benzo [d] imidazole compounds as inhibitors of b-raf kinase
WO2006136823A1 (en) 2005-06-21 2006-12-28 Astex Therapeutics Limited Heterocyclic containing amines as kinase b inhibitors
CA2629136C (en) * 2005-11-08 2016-03-08 Choongwae Pharma Corporation .alpha.-helix mimetics and method relating to the treatment of cancer stem cells
EP1878724A1 (en) 2006-07-15 2008-01-16 sanofi-aventis A regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles
CA2671543A1 (en) 2006-12-05 2008-06-12 Chung-Ming Sun Indazole compounds
MX2009013753A (es) 2007-06-26 2010-01-26 Sanofi Aventis Una sintesis regioselectiva catalizada por cobre de bencimidazoles y azabencimidazoles.
TW200922569A (en) 2007-08-10 2009-06-01 Genelabs Tech Inc Certain nitrogen containing bicyclic chemical entities for treating viral infections
EP2234486A4 (en) 2007-12-19 2011-09-14 Scripps Research Inst BENZIMIDAZOLES AND ANALOGS AS INHIBITORS OF RHO-KINASE
US8501957B2 (en) 2008-12-10 2013-08-06 China Medical University Benzimidazole compounds and their use as anticancer agents
US20110237633A1 (en) 2008-12-11 2011-09-29 Bijoy Panicker Small molecule modulators of hepatocyte growth factor (scatter factor) activity
US20120040916A1 (en) 2008-12-22 2012-02-16 Massachusetts Institute Of Technology Molecular inhibitors of the wnt/beta-catenin pathway
US20120263646A1 (en) 2009-10-15 2012-10-18 Guerbet Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
US9005670B2 (en) * 2010-01-05 2015-04-14 The Johns Hopkins University Use of histone acetyltransferase inhibitors as novel anti-cancer therapies
US8455516B2 (en) 2010-01-15 2013-06-04 Touro University HIV-1 fusion inhibitors and methods
WO2011097607A1 (en) 2010-02-08 2011-08-11 Southern Research Institute Anti-viral treatment and assay to screen for anti-viral agent
WO2011143129A1 (en) 2010-05-13 2011-11-17 Amgen Inc. Nitrogen- heterocyclic compounds as phosphodiesterase 10 inhibitors
EP2397471A1 (en) 2010-06-16 2011-12-21 China Medical University Benzimidazole compounds and their use
WO2012036168A1 (ja) 2010-09-14 2012-03-22 北海道公立大学法人札幌医科大学 筋ジストロフィーを処置するための組成物
WO2012107465A1 (en) 2011-02-09 2012-08-16 F. Hoffmann-La Roche Ag Heterocyclic compounds as pi3 kinase inhibitors
ES2786298T3 (es) 2011-03-03 2020-10-09 Zalicus Pharmaceuticals Ltd Inhibidores de benzimidazol del canal de sodio
JP2014114212A (ja) 2011-03-29 2014-06-26 Dainippon Sumitomo Pharma Co Ltd 新規ベンズイミダゾール誘導体
TW201348231A (zh) 2012-02-29 2013-12-01 Amgen Inc 雜雙環化合物
WO2013186229A1 (en) 2012-06-11 2013-12-19 Ucb Pharma S.A. Tnf -alpha modulating benzimidazoles
US9212209B2 (en) 2012-07-13 2015-12-15 Indiana University Research And Technology Corporation Screening methods for spinal muscular atrophy
JP2016000697A (ja) 2012-10-02 2016-01-07 大日本住友製薬株式会社 ピリミジン誘導体
JP2014073982A (ja) 2012-10-03 2014-04-24 Dainippon Sumitomo Pharma Co Ltd 新規ベンズイミダゾール誘導体からなる医薬
EP2919770A4 (en) 2012-11-14 2017-03-08 The Board of Regents of The University of Texas System Inhibition of hif-2 heterodimerization with hif1 (arnt)
WO2014157382A1 (ja) 2013-03-29 2014-10-02 味の素株式会社 スフィンゴシンキナーゼ阻害剤
PL231063B1 (pl) 2013-04-10 2019-01-31 Oncoarendi Therapeutics Spolka Z Ograniczona Odpowiedzialnoscia Pochodne 1-(podstawionej sulfonylo)-2-aminoimidazoliny jako środki przeciwnowotworowe
TWI527811B (zh) 2013-05-09 2016-04-01 吉李德科學股份有限公司 作爲溴結構域抑制劑的苯並咪唑衍生物
US9662311B2 (en) 2013-06-21 2017-05-30 Zenith Epigenetics Ltd. Substituted bicyclic compounds as bromodomain inhibitors
US10471139B2 (en) 2013-08-15 2019-11-12 The University Of Kansas Toll-like receptor agonists
GB201321741D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
US11447486B2 (en) 2014-07-31 2022-09-20 Institut Pasteur Korea 2-amino-benzimidazole derivatives and their use as 5-lipoxygenase and/or prostaglandin E synthase inhibitors
US10875833B2 (en) 2015-06-12 2020-12-29 Transitions Optical, Inc. Alignment compounds
KR102784592B1 (ko) 2015-08-12 2025-03-19 에피제네틱스, 인크. 치환된 벤즈이미다졸, 그의 제조법 및 제약으로서의 그의 용도
AU2016329075A1 (en) 2015-10-02 2018-04-26 Gilead Sciences, Inc. Combinations of the BTK inhibitor GS-4059 with inhibitors selected from a JAK, ASK1, BRD and/or MMP9 inhibitor to treat cancer, allergic disorders, autoimmune diseases or inflammatory diseases
US20180354909A1 (en) 2015-12-11 2018-12-13 The Board Of Regents Of The University Of Texas System Substituted benzimidazolium, pyrido-imidazolium, or pyrazino-imidazolium compounds as chemotherapeutics
WO2017106568A1 (en) 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and a bromodomain inhibitor for treating cancer
JP7084624B2 (ja) 2016-06-21 2022-06-15 エックス４ ファーマシューティカルズ， インコーポレイテッド Ｃｘｃｒ４阻害剤およびその使用
CA3027500A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
GB201617630D0 (en) 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
WO2018097976A1 (en) 2016-11-22 2018-05-31 Gilead Sciences, Inc. Synthesis of a compound that modulates the activity of bromodomain-containing proteins

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016086200A1 (en) 2014-11-27 2016-06-02 Genentech, Inc. 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
WO2016170323A1 (en) 2015-04-20 2016-10-27 Cellcentric Ltd Isoxazolyl substituted imidazopyridines
WO2016170324A1 (en) 2015-04-20 2016-10-27 Cellcentric Ltd Isoxazolyl substituted benzimidazoles
WO2018073587A1 (en) 2016-10-18 2018-04-26 Cellcentric Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
EP3529248A1 (en) 2019-08-28
CA3039641A1 (en) 2018-04-26
KR20190075095A (ko) 2019-06-28
LT3529248T (lt) 2020-10-26
US20200407349A1 (en) 2020-12-31
ZA201902334B (en) 2022-10-26
CY1123666T1 (el) 2022-03-24
PT3529248T (pt) 2020-09-03
HRP20201444T1 (hr) 2020-12-11
CN110049983A (zh) 2019-07-23
KR102578786B1 (ko) 2023-09-15
US10696666B2 (en) 2020-06-30
DK3529248T3 (da) 2020-09-14
WO2018073586A1 (en) 2018-04-26
MX2019004113A (es) 2019-09-09
BR112019007834A2 (pt) 2019-07-16
EA201990643A1 (ru) 2019-11-29
CN110049983B (zh) 2022-06-14
AU2017346453B2 (en) 2022-02-17
AU2017346453A1 (en) 2019-05-02
IL266017B (en) 2021-08-31
US11377443B2 (en) 2022-07-05
US20190375740A1 (en) 2019-12-12
IL266017A (en) 2019-06-30
EP3529248B1 (en) 2020-08-19
SI3529248T1 (sl) 2020-11-30
ES2828504T3 (es) 2021-05-26
HUE052443T2 (hu) 2021-04-28
GB201617630D0 (en) 2016-11-30
NZ752354A (en) 2025-02-28
SMT202000593T1 (it) 2020-11-10
JP2019537571A (ja) 2019-12-26
MX384438B (es) 2025-03-14
SG11201903155XA (en) 2019-05-30
RS61007B1 (sr) 2020-11-30

Similar Documents

Publication Publication Date Title
JP7152393B2 (ja) 医薬化合物
JP6871864B2 (ja) イソオキサゾリル置換ベンズイミダゾール類
TWI713847B (zh) 治療活性組合物及其使用方法
EP3529240B1 (en) Pharmaceutical compounds
RS57641B1 (sr) Aminoheteroaril benzamidi kao inhibitori kinaze
BR112019007834B1 (pt) Compostos farmacêuticos
EA041318B1 (ru) Арилимидазолилизоксазолы и их применение
EP4480477A1 (en) Pharmaceutical composition for treating cancer, comprising anticancer agent and novel compound having inhibitory activity with respect to prostaglandin e2 receptors
HK40006202A (en) Pharmaceutical compounds
HK40006202B (en) Pharmaceutical compounds
HK40005627A (en) Pharmaceutical compounds
HK40005627B (en) Pharmaceutical compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190611

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20190611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201014

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201014

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210909

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220705

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220906

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220929

R150 Certificate of patent or registration of utility model

Ref document number: 7152393

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250